Heraeus Kulzer Gmbh & Co. Kg

Thommen Medical Ag

Eth Zurich

Gruenenthal Gmbh

Heraeus Kulzer Gmbh

Julius-maximilians-universitaet Wuerzburg

Curasan Ag

Nexilis Ag

Biovotec As

Julius-maximilians-universitaet

Herseus Kulzer Gmbh

Biomedical Apherese Systeme Gmbh

Julius-maximilians-universitat Wurzburg

Berlirem Gmbh

Verein Zur Förderung Von Innovationen Durch Forschung, Entwicklung Und Technologietransfer E.v. (verein Innovent E.v.)

Matthias Schnabelrauch

Sebastian Vogt

Klaus-Dieter Kühn

Falko Schlottig

Lorenz Meinel

Armin Rex Kautz

Ralf Wyrwa

Marcy Zenobi-Wong

Jana Becher

Stefanie Moller

Rami Mhanna

Gemma Palazzolo

Enda Kenny

Ute Moellmann

Ralf Schmidt

Henri-Pierre Suso

Norbert Buske

Lothar Heinisch

Rolf Reissbrodt

Dieter Reif

Klaus H&ouml;ffken

Thomas Seemann

Claudia Rode

Jennifer Ritzer

Thomas Kober

Christian Gansau

Peter G&ouml;rnert

Kay-Oliver Kliche

Joachim Clement

Dimitri Berkov

Michael Bahr

Thorsten Laube

Annika Wartenberg

Kerstin Wagner

Ulrich Bayer

Christian Schrader

Angelika Henning

Christoph VÖLKEL

Jürgen Weisser

Stefanie MÖLLER

Jürgen Schmidt

Johannes Tack

Klaus-Dieter Kuehn

It is an object of the present invention to introduce carboxylic acid-functionalities suitable for coupling into the denatonium structure by means of simple synthesis, namely the synthesis of bitter principle derivatives based on the denatonium structure according to formula 1: For example, according to the invention, lidocaine derivatives may be reacted with carboxylated benzyl halogenides. The carboxylated denatonium derivatives of the present invention are especially applied in medicine, biology, medical engineering as well as cosmetics, the pharmaceutical, chemical, and foodstuff industry.

Production of bitter principle derivatives

The invention provides a three dimensional (3D), porous, biodegradable and biocompatible tissue engineering scaffold, wherein at least 25% w/w of the scaffold is particulate egg shell membrane (ESM) distributed substantially uniformly therein and the scaffold is essentially dry. Methods for preparing the same by freeze-drying and cryogelation and the use thereof in methods of tissue engineering and to promote the healing of wounds are also provided.

Tissue engineering scaffolds comprising particulate egg shell membrane

The present invention relates to a method for providing an embedded mammalian cell, comprising the steps of providing an alginate sulfate in aqueous solution; reacting the alginate sulfate to form a hydrogel in a gelation step, providing a precursor cell, and embedding the precursor cell in the sulfated alginate hydrogel in an embedding step, thus yielding an sulfated alginate hydrogel embedded cell. The invention further relates to sulfated alginate hydrogels, and cellular grafts comprising a mammalian cell embedded in sulfated alginate hydrogel.

Sulfated alginate hydrogels for cell culture and therapy

The document proposes a diagnostic chewing gum for identifying the presence of inflammatory tissues in the mouth, in particular in or adjacent to the mandible, the maxilla, an implant or the teeth of a user, comprising a base material or particles () embedded and/or attached to the base material; an element (,-), like e.g. a releasable flavor molecule, attached to the base material and/or the particles, for the generation of a change in the chewing gum directly detectable by the user; wherein the element (,-) generates the change upon direct or indirect contact with a marker (), e.g. a proteolytic enzyme, which is released by inflammatory tissue in response to bacterial mediators.

Device for the diagnosis of inflammatory tissues in dental applications

Described herein is a diagnostic chewing gum for identifying the presence of pathogens detectable via the mouth, in particular pathogens residing in nasal, oropharyngeal, laryngeal, oesophageal, ocular and/or pulmonal tissue of a user, more particularly pathogens selected from among a virus, bacterium, protozoa, prion, fungus or a combination thereof. The inventive diagnostic chewing gum includes a base material or particles () embedded and/or attached to the base material and an element (-), like e.g. a releasable flavor molecule, attached to the base material and/or the particles, for the generation of a change in the chewing gum directly detectable by the user, wherein the element (-) generates the change upon direct or indirect contact with a marker () which is released by the pathogens, or, in case of a virus or prion, by the cellular structure hosting it.

Diagnostic chewing gum for pathogens

The invention relates to an implant, e.g. a stent, bone replacement material, a prosthesis, a scaffold or similar, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterized in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component. The invention also relates to a method for producing an implant of this type and to a specific composition, which can be used to produce a coating of this type.

Implant and production method for said implant

The invention relates to a dental implant, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterized in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component. The invention also relates to a method for producing a dental implant of this type and to a specific composition, which can be used to produce a coating of this type.

Dental implant and production method for said implant

A method of producing a self-hardening, bioabsorbable composite material, the material produced and its areas of application are described. The method is based on the principal method steps (I) immobilisation of a polymerisation initiator in a microporous pore system of a first partial amount of a bioabsorbable calcium phosphate used in producing the self-hardening, bioabsorbable composite material, (II) immobilisation of a polymerisation activator in the microporous pore system of a second partial amount of the bioabsorbable calcium phosphate used in producing the self-hardening, bioabsorbable composite material and (III) homogeneous mixing of the components according to (I) and (II) with a liquid or paste-form, multi-functional monomer capable of forming a biocompatible, bioabsorbable polymer network or a corresponding monomer mixture and, optionally, with further constituents which modify the properties of the monomer or monomer mixture. The described self-hardening, bioabsorbable composite materials can be used as bone adhesives for the fixing of bone fractures, as shaped pieces of standardised dimensions and as implants that are individual to a patient in the context of regenerative bone healing in humans and animals.

Bioabsorbable composite material

What is described is an implant that comprises a coating, at least in areas, in the implanted state in the surface areas that are at least directly in contact with skin and/or soft tissue. The implant is preferably characterized in that the coating comprises both a statin, such as simvastatin, in the hydrolyzed or unhydrolyzed form, or pharmaceutically compatible salts thereof, as well as at least one other component selected from the group consisting of branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl, alkenyl, alkylaryl, aryl, cycloalkyl, alkylcycloalkyl, alkylcycloaryl amines or mixtures thereof and/or at least one water-soluble ionic polymer component. A method for production such an implant is also described as well as a composition that can be used in such a method.

Implant and method for the manufacture thereof

An antibiotic coating of implants is described, which is characterized in that the coating comprises at least one saturated, organic, hydrophobic, low molecular matrix former whose melting point is in the temperature range of 45&#xb0; C. to 100&#xb0; C., in which a low molecular, hydrophobic additive is dissolved and that an antibiotic/antibiotics is/are suspended in the mixture of matrix former and additive and/or in which an antibiotic/antibiotics miscible with a mixture of matrix former and additive is/are dissolved.

Antibiotic coating of implants

The invention relates to a method for the antibiotic coating of bodies with interconnecting microcavities as well as bodies coated this way and their usage. The invented method is characterized in that in the microcavities of non-metallic bodies an aqueous solution 1, which contains at least one easily water-soluble antibiotic component from the groups of the aminoglycoside antibiotics, the tetracycline antibiotics, the lincosamide antibiotics and the 4-quinolone antibiotics, and an aqueous solution 2, which contains at least one easily water-soluble amphiphilic component from the groups of the alkyl sulfates, alkyl sulfonates, alkylaryl sulfates, dialkylaryl sulfates, alkylaryl sulfonates, dialkylaryl sulfonates, cycloalkyl sulfates, cycloalkyl sulfonates, alkylcycloalkyl sulfates, are introduced, wherein between the introduction of solutions 1 and 2 the water is basically removed through vaporization and/or evaporation, and whereby from the components of solutions 1 and 2 in the microcavities a deposit is formed, which is sparingly soluble in water.

Method for the antibiotic coating of bodies with interconnecting microcavities as well as coated bodies and their usage

The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs. The invention describes antiphlogistic-antibiotic pharmaceutical preparations for which mixtures in the solid state of aggregation are used, which are composed of an easily water soluble salt of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicycline, oxytetracycline and/or rolitetracycline and at least one easily water soluble salt of ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate and at least one inorganic and/or organic pharmaceutical adjuvant and which are used as permanent or temporary implants in the form of tablets and/or molded bodies.

Pharmaceutical preparation, method for its production as well as its use

The invention describes pharmaceutical preparations with retarding active ingredient release, which consist of mixtures of powdery teicoplanin and at least one powdery, water soluble salt form of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin and an inorganic and/or organic adjuvant. The pharmaceutical preparations are used as permanent or as temporary implants in the form of tablets, molded bodies, fibers and granules.

Pharmaceutical preparation with retarding active ingredient release, method for its production and its use

The invention describes an antibiotic coating for porous bodies and its use. Into the porous system of non-metallic porous bodies and of metallic porous bodies, a coating made of at least one antibiotic salt that is hardly soluble in water or in an aqueous environment from the group of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate, the kanamycin dodecyl sulfate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the ciprofloxacin myristate, the vancomycin dodecyl sulfate, the vancomycin laurate, the vancomycin myristate, the vancomycin teicoplanin and the clindamycin teicoplanin is introduced. The antibiotically coated, porous bodies are used as implants.

Antibiotic coating for porous bodies and method for its production as well as its use

Growing community of inventors

Jena, Germany

Matthias Schnabelrauch